BioNTech and DualityBio join hands to develop two ADCs for Solid tumors

CAR-T Digest - August 2020

03 Apr 2023: DB-1303 / DB-1311 / Solid Tumors / BioNTech / DualityBio: Collaboration to co-develop two antibody-drug conjugate assets

BioNTech received exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets DB-1303 (HER2-Targeting ADC) and DB-1311 (Second Topoisomerase-1 Inhibitor-Based ADC)
The DB-1303 program received the US FDA Fast Track designation and is currently in Phase 2 clinical trial for HER2-expressing advanced solid tumors
Collaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stage oncology portfolio, expanding the breadth of its immunotherapy toolkit with synergistic potential
DualityBio received upfront payments totaling $170 million, and will be eligible to receive development, regulatory, and commercial milestone payments potentially totaling over $1.5 billion as well as single-digit to double-digit tiered royalties on potential future product sales